The Audacious Medical Grant (AMG) is a funding tool financed by private donations and legacies received by the FNRS.
It supports medical or biomedical research projects that are original, daring and creative, but which do not find support in traditional funding channels because of a lack of preliminary data, absence of previous work or unusual methodology.
The term "bold" means that there is a significant risk that the project will produce little or no tangible scientific result because of its novelty or complexity.
The AMG-Oncology is not a Télévie-dependent funding instrument but the FNRS uses the expertise of its Scientific Commission to conduct the evaluation of submitted projects. There is therefore no notion of cumulation between the AMG-ONCO 2023 call and the Télévie 2023 call.